

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
3.0	06/18/2025	11474868-00003	Date of first issue: 11/26/2024

### SECTION 1. IDENTIFICATION

Product name : Cefalexin Formulation

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Respiratory sensitization : Category 1  
Reproductive toxicity : Category 2  
Specific target organ toxicity : Category 3  
- single exposure  
Specific target organ toxicity : Category 2 (Kidney, Adrenal gland, Blood, Gastrointestinal tract)  
- repeated exposure

#### Other hazards

None known.

#### GHS label elements

Hazard pictograms	:
Signal Word	: Danger
Hazard Statements	: H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. H335 May cause respiratory irritation. H361f Suspected of damaging fertility. H373 May cause damage to organs (Kidney, Adrenal gland, Blood, Gastrointestinal tract) through prolonged or repeated exposure.
Precautionary Statements	: <b>Prevention:</b> P201 Obtain special instructions before use.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version 3.0      Revision Date: 06/18/2025      SDS Number: 11474868-00003      Date of last issue: 04/14/2025  
Date of first issue: 11/26/2024

P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe mist or vapors.  
P271 Use only outdoors or in a well-ventilated area.  
P280 Wear protective gloves, protective clothing, eye protection and face protection.  
P285 In case of inadequate ventilation wear respiratory protection.

### Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a doctor if you feel unwell.

P308 + P313 IF exposed or concerned: Get medical attention.

P342 + P311 If experiencing respiratory symptoms: Call a doctor.

### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Cefalexin	15686-71-2*	>= 10 - <= 30	TSC

\* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

## SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
If not breathing, give artificial respiration.  
If breathing is difficult, give oxygen.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
3.0	06/18/2025	11474868-00003	Date of first issue: 11/26/2024

- |   |   |
|---|---|
| In case of eye contact                                      | : Flush eyes with water as a precaution.<br>Get medical attention if irritation develops and persists.  |
| If swallowed  | : If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.   |
| Most important symptoms and effects, both acute and delayed | : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).<br>May cause allergy or asthma symptoms or breathing difficulties if inhaled.<br>May cause respiratory irritation.<br>Suspected of damaging fertility.<br>May cause damage to organs through prolonged or repeated exposure. |
| Protection of first-aiders                                  | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).   |
| Notes to physician  | : Treat symptomatically and supportively.   |

### SECTION 5. FIRE-FIGHTING MEASURES

- |  |   |
|--|---|
| Suitable extinguishing media                   | : Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media                 | : None known.   |
| Specific hazards during fire fighting          | : Exposure to combustion products may be a hazard to health.  |
| Hazardous combustion products                  | : Carbon oxides<br>Nitrogen oxides (NO <sub>x</sub> )<br>Sulfur oxides  |
| Specific extinguishing methods                 | : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do so.<br>Evacuate area. |
| Special protective equipment for fire-fighters | : In the event of fire, wear self-contained breathing apparatus.<br>Use personal protective equipment.  |

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- |   |  |
|---|--|
| Personal precautions, protective equipment and emergency procedures | : Use personal protective equipment.<br>Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions   | : Avoid release to the environment.  |

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
3.0	06/18/2025	11474868-00003	Date of first issue: 11/26/2024

Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g., by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	: Do not breathe mist or vapors. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers. Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage	: Keep in properly labeled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents Gases

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version 3.0      Revision Date: 06/18/2025      SDS Number: 11474868-00003      Date of last issue: 04/14/2025  
Date of first issue: 11/26/2024

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cefalexin	15686-71-2	TWA	550 µg/m <sup>3</sup> (OEB 2)	Internal
Further information: RSEN				

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Laboratory operations do not require special containment.

#### Personal protective equipment

**Respiratory protection** : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**  
**Material** : Chemical-resistant gloves

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.  
**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
3.0	06/18/2025	11474868-00003	Date of first issue: 11/26/2024

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: liquid
Color	: clear
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: No data available
Relative vapor density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: No data available
Autoignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Explosive properties	: Not explosive

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
3.0	06/18/2025	11474868-00003	Date of first issue: 11/26/2024

Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	Not applicable

### SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity	:	Acute toxicity estimate: 2,381 mg/kg Method: Calculation method
---------------------	---	--

#### Components:

##### Cefalexin:

Acute oral toxicity	:	LD50 (Mouse): 1,600 - 6,200 mg/kg  LD50 (Dog): > 2,000 mg/kg Symptoms: Vomiting  LD50 (Monkey): > 1,000 mg/kg Symptoms: Vomiting  LD50 (Rat): > 20,000 mg/kg
Acute toxicity (other routes of administration)	:	LD50 (Dog): > 1 g/kg Application Route: Intraperitoneal  LD50 (Dog): > 0.1 g/kg Application Route: Intravenous

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
3.0	06/18/2025	11474868-00003	Date of first issue: 11/26/2024

### II

#### Skin corrosion/irritation

Not classified based on available information.

#### Serious eye damage/eye irritation

Not classified based on available information.

#### Respiratory or skin sensitization

##### Skin sensitization

Not classified based on available information.

##### Respiratory sensitization

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

#### Components:

##### Cefalexin:

Assessment	:	Probability or evidence of high respiratory sensitization rate in humans
------------	---	--

Remarks	:	Based on data from similar materials May cause sensitization by inhalation.
---------	---	--

Result	:	Sensitizer
--------	---	------------

Remarks	:	Based on data from similar materials May cause sensitization by inhalation.
---------	---	--

#### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Cefalexin:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	--

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: mouse lymphoma cells  
Result: negative

Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Result: negative
----------------------	---	--

#### Carcinogenicity

Not classified based on available information.

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.



# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
3.0	06/18/2025	11474868-00003	Date of first issue: 11/26/2024

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### Reproductive toxicity

Suspected of damaging fertility.

#### Components:

##### Cefalexin:

Effects on fertility	: Test Type: Two-generation study Species: Rat Application Route: Oral Fertility: NOAEL: 250 mg/kg body weight Result: May cause adverse reproductive effects., Reduced fertility of F1 generation.
Effects on fetal development	: Test Type: Development Species: Mouse Application Route: Oral Embryo-fetal toxicity.: NOAEL: 400 mg/kg body weight Remarks: No significant adverse effects were reported Maternal toxicity observed.  Test Type: Development Species: Rat Application Route: Oral Embryo-fetal toxicity.: NOAEL: 1,200 mg/kg body weight Remarks: No significant adverse effects were reported Maternal toxicity observed.
Reproductive toxicity - Assessment	: Suspected of damaging fertility.

### STOT-single exposure

May cause respiratory irritation.

#### Components:

##### Cefalexin:

Routes of exposure	: Inhalation
Assessment	: May cause respiratory irritation.

### STOT-repeated exposure

May cause damage to organs (Kidney, Adrenal gland, Blood, Gastrointestinal tract) through prolonged or repeated exposure.

#### Components:

##### Cefalexin:

Target Organs	: Kidney, Adrenal gland, Blood, Gastrointestinal tract
Assessment	: May cause damage to organs through prolonged or repeated

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
3.0	06/18/2025	11474868-00003	Date of first issue: 11/26/2024

II exposure.

### Repeated dose toxicity

#### Components:

##### Cefalexin:

Species	: Rat
NOAEL	: < 160 mg/kg
Application Route	: Oral
Target Organs	: Kidney, Adrenal gland, Blood
Symptoms	: Vomiting, Diarrhea, Kidney disorders, Blood disorders

Species	: Dog
NOAEL	: < 160 mg/kg
Application Route	: Oral
Target Organs	: Kidney, Adrenal gland, Blood
Symptoms	: Vomiting, Diarrhea, Blood disorders, Kidney disorders

Species	: Monkey
NOAEL	: < 160 mg/kg
Application Route	: Oral
Target Organs	: Kidney, Adrenal gland, Blood
Symptoms	: Vomiting, Diarrhea, Blood disorders, Kidney disorders

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### Cefalexin:

Inhalation	: Target Organs: Respiratory Tract Remarks: May cause irritation of respiratory tract. May cause sensitization by inhalation.
Ingestion	: Target Organs: Gastrointestinal tract Symptoms: The most common side effects are:, Nausea, Vomiting, Abdominal pain, Diarrhea, liver function change, blood effects

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

##### Cefalexin:

#### Ecotoxicology Assessment

Acute aquatic toxicity	: Toxic effects cannot be excluded
Chronic aquatic toxicity	: Toxic effects cannot be excluded

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
3.0	06/18/2025	11474868-00003	Date of first issue: 11/26/2024

### Persistence and degradability

No data available

### Bioaccumulative potential

No data available

### Mobility in soil

No data available

### Other adverse effects

No data available

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues	:	Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

UN/ID No.	:	UN 3334
Proper shipping name	:	Aviation regulated liquid, n.o.s. (Cefalexin)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	964
Packing instruction (passenger aircraft)	:	964

#### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

### Domestic regulation

#### 49 CFR

Not regulated as a dangerous good

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
3.0	06/18/2025	11474868-00003	Date of first issue: 11/26/2024

### SECTION 15. REGULATORY INFORMATION

#### CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

#### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

#### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Respiratory or skin sensitization  
Reproductive toxicity  
Specific target organ toxicity (single or repeated exposure)

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

#### US State Regulations

##### Pennsylvania Right To Know

Cefalexin

15686-71-2

##### The ingredients of this product are reported in the following inventories:

DSL : not determined

AICS : not determined

IECSC : not determined

### SECTION 16. OTHER INFORMATION

#### Further information

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation


Version  
3.0

Revision Date:  
06/18/2025

SDS Number:  
11474868-00003

Date of last issue: 04/14/2025  
Date of first issue: 11/26/2024

### NFPA 704:



### HMIS® IV:

HEALTH	*	2
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

### Full text of other abbreviations

AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Cefalexin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
3.0	06/18/2025	11474868-00003	Date of first issue: 11/26/2024

---

(United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 06/18/2025

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8